|
CA2871886A1
|
|
Amorphous dispersions of paroxetine mesylate
|
|
WO2014138905A1
|
|
Forms of sorafenib tosylate and processes for the preparation thereof
|
|
WO2014121383A1
|
|
A process for the preparation of rufinamide and intermediates thereof
|
|
AU2013213755A1
|
|
Crystalline d-isoglutamyl-d-tryptophan and the mono ammonium salt of d-isoglutamyl-d-tryptophan
|
|
WO2013155595A1
|
|
Process for the preparation of a monosodium salt of h-d-glu-(l-trp-oh)-oh and a crystalline form thereof
|
|
WO2013155592A1
|
|
Crystal forms of golotimod and process for its manufacturing
|
|
WO2013123574A1
|
|
Orally bioavailable derivatives of d-gamma-glutamyl-d-tryptophan
|
|
WO2013075015A1
|
|
Methods of treatment with deferiprone
|
|
EP2691369A1
|
|
Prodrugs of d-isoglutamyl-[d/l]-tryptophan
|
|
CA2831429A1
|
|
Prodrugs of d-gamma-glutamyl-d-tryptophan and d-gamma- glutamyl-l-tryptophan
|
|
WO2011050436A1
|
|
Particle size distribution determination apparatus and method
|
|
CA2653011A1
|
|
Method and apparatus for packaging and dispensing pharmaceuticals
|
|
MY150608A
|
|
Liquid formulation for deferiprone with platable taste
|
|
SG190579A1
|
|
Liquid formulation for deferiprone with palatable taste
|
|
UA102254C2
|
|
Normal;heading 1;heading 2;heading 3;LIQUID FORMULATION FOR DEFERIPRONE WITH PALATABLE TASTE
|
|
MX2009010407A
|
|
Fluorinated derivatives of deferiprone.
|
|
EP1991225A1
|
|
The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron
|
|
CA2579119A1
|
|
Crystalline forms of the mono-sodium salt of d-isoglutamyl-d-tryptophan
|
